Jiaying Li

Jiaying Li

Auto-generated profile, based on publicly available information

Jiaying Li

Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Guangdong (J.L.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2020 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
DCDi Chen
Di Chen
YHYichen Huang
Yichen Huang
ZSZiyu Shi
Ziyu Shi
JLJiaying Li
Jiaying Li
YZYue Zhang
Yue Zhang
YGYanqin Gao
Yanqin Gao
Demyelination occurs in response to brain injury and is observed in many neurodegenerative diseases. Myelin is synthesized from oligodendrocytes in the central nervous system, and oligodendrocyte death‐induced demyelination is one of the mechanisms involved in white matter damage after stroke and neurodegeneration. Oligodendrocyte precursor cells (OPCs) exist in the brain of normal adults, and their differentiation into mature oligodendrocytes play a central role in remyelination. Although the differentiation and maturity of OPCs drive endogenous efforts for remyelination, the failure of axons to remyelinate is still the biggest obstacle to brain repair after injury or diseases. In recent years, studies have made attempts to promote remyelination after brain injury and disease, but its cellular or molecular mechanism is not yet fully understood. In this review, we discuss recent studies examining the demyelination process and potential therapeutic strategies for remyelination in aging and stroke. Based on our current understanding of the cellular and molecular mechanisms underlying remyelination, we hypothesize that myelin and oligodendrocytes are viable therapeutic targets to mitigate brain injury and to treat demyelinating‐related neurodegeneration diseases.

2 March 2021 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
KWKe Wang
Ke Wang
JLJiaying Li
Jiaying Li
YZYue Zhang
Yue Zhang
YHYichen Huang
Yichen Huang
DCDi Chen
Di Chen
YGYanqin Gao
Yanqin Gao
Microglia are important phagocytes of the central nervous system (CNS). They play an important role in protecting the CNS by clearing necrotic tissue and apoptotic cells in many CNS diseases. However, recent studies have found that microglia can phagocytose parts of neurons excessively, such as the neuronal cell body, synapse, or myelin sheaths, before or after the onset of CNS diseases, leading to aggravated injury and impaired tissue repair. Meanwhile, reduced phagocytosis of synapses and myelin results in abnormal circuit connections and inhibition of remyelination, respectively. Previous studies focused primarily on the positive effects of microglia phagocytosis, whereas only a few studies have focused on the negative effects. In this review, we use the term "pathological microglial phagocytosis" to refer to excessive or reduced phagocytosis by microglia that leads to structural or functional abnormalities in target cells and brain tissue. The classification of pathological microglial phagocytosis, the composition, and activation of related signaling pathways, as well as the process of pathological phagocytosis in various kinds of CNS diseases, are described in this review. We hypothesize that pathological microglial phagocytosis leads to aggravation of tissue damage and negative functional outcome. For example, excessive microglial phagocytosis of synapses can be observed in Alzheimer's disease and schizophrenia, leading to significant synapse loss and memory impairment. In Parkinson's disease, ischemic stroke, and traumatic brain injury, excessive microglial phagocytosis of neuronal cell bodies causes impaired gray matter recovery and sensory dysfunction. We therefore believe that more studies should focus on the mechanism of pathological microglial phagocytosis and activation to uncover potential targets of therapeutic intervention.

8 March 2024 in Science Advances
Verified
Journal Article
Open access
YZYue Zhang
Yue Zhang
JLJiaying Li
Jiaying Li
YZYongfang Zhao
Yongfang Zhao
YHYichen Huang
Yichen Huang
ZSZiyu Shi
Ziyu Shi
YGYanqin Gao
Yanqin Gao
The accumulation of self-renewed polarized microglia in the penumbra is a critical neuroinflammatory process after ischemic stroke, leading to secondary demyelination and neuronal loss. Although known to regulate tumor cell proliferation and neuroinflammation, HDAC3’s role in microgliosis and microglial polarization remains unclear. We demonstrated that microglial HDAC3 knockout (HDAC3-miKO) ameliorated poststroke long-term functional and histological outcomes. RNA-seq analysis revealed mitosis as the primary process affected in HDAC3-deficent microglia following stroke. Notably, HDAC3-miKO specifically inhibited proliferation of proinflammatory microglia without affecting anti-inflammatory microglia, preventing microglial transition to a proinflammatory state. Moreover, ATAC-seq showed that HDAC3-miKO induced closing of accessible regions enriched with PU.1 motifs. Overexpressing microglial PU.1 via an AAV approach reversed HDAC3-miKO–induced proliferation inhibition and protective effects on ischemic stroke, indicating PU.1 as a downstream molecule that mediates HDAC3’s effects on stroke. These findings uncovered that HDAC3/PU.1 axis, which mediated differential proliferation-related reprogramming in different microglia populations, drove poststroke inflammatory state transition, and contributed to pathophysiology of ischemic stroke.

1 September 2021 in Neurochemistry International
Verified
Journal Article
Closed access
QLQi-Qi Li
Qi-Qi Li
JLJia-Ying Li
Jia-Ying Li
MZMing Zhou
Ming Zhou
ZQZheng-Hong Qin
Zheng-Hong Qin
RSRui Sheng
Rui Sheng

1 November 2026 in Stroke
Verified
Journal Article
Closed access
QCQiankang Chen
Qiankang Chen
SYShihao Yuan
Shihao Yuan
YWYana Wang
Yana Wang
JLJiaying Li
Jiaying Li
XCXingdong Chen
Xingdong Chen
YGYanqin Gao
Yanqin Gao
BACKGROUND: Chronic cerebral hypoperfusion is a major driver of vascular cognitive impairment (VCI), but the role of microglial purinergic signaling in chronic cerebral hypoperfusion–induced neurovascular dysfunction remains undefined. This hypothesis-testing study with a novel research premise aimed to address this knowledge gap by clarifying whether microglial P2Y12 (purinergic receptor P2Y12), a microglia-enriched G-protein–coupled receptor, mediates VCI pathogenesis through regulation of microglial calcium signaling and microglia-vascular crosstalk under chronic cerebral hypoperfusion conditions. METHODS: VCI was induced in adult male mice by asymmetrical bilateral carotid artery stenosis. Microglia-specific P2Y12 knockout mice were generated using P2Y12 flox/flox :CX3CR1 (CX3C chemokine receptor 1) CreER mice. Cognitive function was assessed by object location recognition, 3-chamber social interaction, and Morris water maze tests. Cerebral blood flow was measured by laser speckle contrast imaging and functional ultrasound. Neuroinflammation, microvascular integrity, and perivascular microglial Ca 2+ activity were evaluated by immunofluorescence, flow cytometry, and 2-photon GCaMP6f (the fast variant of the genetically encoded calcium indicator GCaMP6) imaging. The clinically approved L-type Ca 2+ channel blocker nimodipine was administered starting 42 days postasymmetrical bilateral carotid artery stenosis. RESULTS: All experimental animals exhibited consistent baseline physiological and behavioral status without intergroup differences throughout the procedure. Chronic cerebral hypoperfusion induced persistent upregulation of P2Y12 in hippocampal microglia. Microglial P2Y12 genetic ablation effectively ameliorated hypoperfusion-triggered cognitive impairment, hippocampal atrophy, and neuronal loss, preserved cerebral perfusion, and inhibited sustained microglial inflammatory activation and pathological microglia-microvessel interaction. Mechanistically, P2Y12 signaling mediated aberrant ATP-triggered Ca 2+ hyperactivity in perivascular microglia, and this pathological phenotype was eliminated by microglial P2Y12 deletion. Pharmacological intervention with nimodipine recapitulated the protective effects of genetic P2Y12 inhibition, normalizing abnormal microglial calcium activity, alleviating neuroinflammation and disruptive microglia-vascular crosstalk, maintaining cerebral structural and perfusion homeostasis, and rescuing cognitive dysfunction in model mice, while exerting no adverse effects on control animals. CONCLUSIONS: The microglial P2Y12/Ca 2+ axis is a critical pathogenic driver of chronic cerebral hypoperfusion–induced VCI, linking sustained microglial activation to neuroinflammation and cerebral microvascular injury. Pharmacological inhibition of this axis with nimodipine recapitulates the benefits of genetic P2Y12 deletion, identifying a clinically translatable therapeutic strategy for VCI treatment. All conclusions are fully supported by the comprehensive behavioral, imaging, and molecular experimental results obtained in this study.